Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Postgrad Med. 2004 Apr-Jun;50(2):140-4.

Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome.

Author information

  • 1Department of Internal Medicine, State University of New York, Buffalo, NY, USA. vbhatia@buffalo.edu

Abstract

It is estimated that 5-10% of women of reproductive age have polycystic ovarian syndrome (PCOS). While insulin resistance is not part of the diagnostic criteria for PCOS, its importance in the pathogenesis of PCOS cannot be denied. PCOS is associated with insulin resistance independent of total or fat-free body mass. Post-receptor defects in the action of insulin have been described in PCOS which are similar to those found in obesity and type 2 diabetes. Treatment with insulin sensitizers, metformin and thiazolidinediones, improve both metabolic and hormonal patterns and also improve ovulation in PCOS. Recent studies have shown that PCOS women have higher circulating levels of inflammatory mediators like C-reactive protein, tumour necrosis factor-alpha, tissue plasminogen activator and plasminogen activator inhibitor-1 (PAI-1). It is possible that the beneficial effect of insulin sensitizers in PCOS may be partly due to a decrease in inflammation.

PMID:
15235215
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Medknow Publications and Media Pvt Ltd
    Loading ...
    Write to the Help Desk